Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference.
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Keros Therapeutics (KROS – Research Report). The ...
Microsoft Corp. has canceled some leases for US data center capacity, according to TD Cowen, raising broader concerns over ...
AllianceBernstein (NYSE:AB) was downgraded at TD Cowen after Equitable Holdings (NYSE:EQH) announced a tender offer for up to ...
Textron (NYSE:TXT – Get Free Report) was upgraded by investment analysts at TD Cowen to a “hold” rating in a report released ...
Mit Blick auf den KI-Nachfrage-Ausblick lässt ein Bericht der Investmentbank TD Cowen aufhorchen: Microsoft hat demnach ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
Domino’s Pizza (NASDAQ:DPZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at TD Cowen in a ...
Microsoft Corp. has canceled some leases for US data center capacity, according to TD Cowen, raising broader concerns over ...
TD Cowen analyst Andrew Sherman raised the firm’s price target on Axon (AXON) to $725 from $700 and keeps a Buy rating on the shares. The firm ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback